Source:http://linkedlifedata.com/resource/pubmed/id/15736428
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2005-3-1
|
pubmed:abstractText |
Many clinical studies have reported that irinotecan has reproducible antitumor activity against lung cancer. Both cisplatin and SN-38 are key drugs in the treatment of lung cancer, and their combination is one of the most promising regimens available. Using lung cancer cell lines, ABC-1 and SBC-3, we examined the cytotoxic effect of the schedule, as well as the effect of cisplatin on topoisomerase I activity. Cytotoxicity was determined by MTT assay. ABC-1 or SBC-3 cells were incubated with or without various concentrations of both drugs in 96-well microplates for 72 or 96 hours in a humidified 5% CO2 atmosphere at 37 degrees C. Synergism was evaluated by median-effect plot analysis and a combination index isobologram method by Chou and Talalay. After ABC-1 or SBC-3 cells had been exposed to 10/microM cisplatin for one hour, topoisomerase I activities were determined by supercoiled-DNA relaxation assay. Synergism was observed in ABC-1 and SBC-3 cells when cisplatin was given first, followed by SN-38 (7-ethyl-10-hydroxycamptothecin) and cisplatin. Topoisomerase I activity decreased at 1-2 hours after exposure to cisplatin and recovered gradually after 4-5 hours of cisplatin exposure in both ABC-1 and SBC-3 cells. Accordingly, pretreatment with cisplatin will have an impact on the sensitivity to SN-38.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Superhelical,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Topoisomerases, Type I,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Topoisomerase I Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/irinotecan
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0250-7005
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
24
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3893-7
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:15736428-Adenocarcinoma,
pubmed-meshheading:15736428-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15736428-Camptothecin,
pubmed-meshheading:15736428-Carcinoma, Small Cell,
pubmed-meshheading:15736428-Cell Line, Tumor,
pubmed-meshheading:15736428-Cisplatin,
pubmed-meshheading:15736428-DNA, Superhelical,
pubmed-meshheading:15736428-DNA Topoisomerases, Type I,
pubmed-meshheading:15736428-Down-Regulation,
pubmed-meshheading:15736428-Drug Administration Schedule,
pubmed-meshheading:15736428-Drug Synergism,
pubmed-meshheading:15736428-Enzyme Inhibitors,
pubmed-meshheading:15736428-Humans,
pubmed-meshheading:15736428-Lung Neoplasms,
pubmed-meshheading:15736428-Topoisomerase I Inhibitors
|
pubmed:articleTitle |
Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines.
|
pubmed:affiliation |
Department of Internal Medicine, Okayama University Medical School, Okayama, Japan. keisukeaoe@mtf.biglobe.ne.jp
|
pubmed:publicationType |
Journal Article
|